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Omphalocele–exstrophy of the bladder-imperforate anus-spinal
defects (OEIS) complex, or cloacal exstrophy (EC), is a rare
constellation of malformations in humans involving the urogen-
ital, gastrointestinal, and skeletal systems, and less commonly
the central nervous system. Although OEIS complex is well-
recognized in the clinical setting, there remains a significant lack
of understanding of this condition at both the developmental and
the genetic level. While most cases are sporadic, familial cases
have been reported, suggesting that one or more specific genes
may play a significant role in this condition. Several develop-
mental mechanisms have been proposed to explain the etiology
of OEIS complex, and it is generally considered to be a defect
early in caudal mesoderm development and ventral body wall
closure. The goal of this study was to identify genetic aberrations
in 13 patients with OEIS/EC using a combination of candidate
gene analysis and microarray studies. Analysis of 14 candidate
genes in combination with either high resolution SNP or oligo-
nucleotide microarray did not reveal any disease-causing muta-
tions, although novel variants were identified in five patients. To
our knowledge, this is the most comprehensive genetic analysis
of patients with OEIS complex to date. We conclude that OEIS is a
complex disorder from an etiological perspective, likely involv-
ing a combination of genetic and environmental predispositions.
Based on our data, OEIS complex is unlikely to be caused by a
recurrent chromosomal aberration.  2010 Wiley-Liss, Inc.
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INTRODUCTION
Omphalocele–exstrophy of the bladder-imperforate anus-spinal
defects (OEIS) complex or cloacal exstrophy (EC), is a rare con-
stellation of malformations involving multiple organ systems in
humans [Carey et al., 1978; Kallen et al., 2000; Keppler-Noreuil,
2001; Martinez-Frias et al., 2001]. The incidence of OEIS complex
is estimated to be 1 in 200,000 live births although this may be
an underestimate of the total number of cases because it lacks
inclusion of stillbirths and pregnancy terminations [Martinez-Frias
et al., 2001; Keppler-Noreuil et al., 2007]. Nevertheless, individuals
born with this malformation complex require immediate
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surgical intervention and suffer from significant long-term
disabilities.
The pathophysiology of OEIS complex is unknown. OEIS/EC
is hypothesized to be part of a spectrum of malformations, also
known as BEEC, which includes bladder exstrophy (BE) and
epispadias. Several hypotheses have been proposed to explain
the developmental mechanisms leading to the phenotypic ex-
pression of OEIS complex and BE [Keppler-Noreuil, 2001;
Martinez-Frias et al., 2001; Bohring, 2002; Siebert et al., 2005;
Sadler and Feldkamp, 2008; Ludwig et al., 2009a]. OEIS complex
is thought to be caused by a defect in caudal mesoderm formation
and migration between the ectodermal and endodermal layers
of the cloacal membrane, leading to premature or abnormal
rupture of the cloacal membrane. The phenotype of OEIS
complex versus BE is hypothesized to be due to the timing of
abnormal cloacal membrane rupture with respect to migration
of the urorectal septum [Jones, 1997; Keppler-Noreuil, 2001].
More recently, it has been proposed that OEIS/EC is due to
failure in closure of the ventral body wall, which occurs during
the third and fourth weeks of development [Sadler and Feldkamp,
2008]. Limb-body wall complex (LBWC) and urorectal septum
malformation sequence (URSMS) also share overlapping
features with OEIS/EC, and it has been hypothesized that they
also share an underlying etiology [Heyroth-Griffis et al., 2007].
Other malformations of the caudal portion of the embryo
share some features with OEIS complex, including vertebral-anal
-cardiac-tracheoesophageal fistula-renal-limb (VACTERL) asso-
ciation and caudal regression syndrome (CRS) [Bohring, 2002;
Siebert et al., 2005]. All of these conditions have an unknown
etiology.
Most cases of OEIS complex are sporadic. However, reports of
familial cases and higher rates of concordance in monozygotic twins
provide support for a genetic etiology [Lee et al., 1999; Keppler-
Noreuil, 2001; Boyadjiev et al., 2004]. Although rare chromosomal
anomalies have been reported and a few candidate genes have been
analyzed in small numbers of patients [Nye et al., 2000; Boyadjiev
et al., 2004, 2005; Reutter et al., 2006; Kruger et al., 2008; El-Hattab
et al., 2010], no causative genes have been identified. Environmental
influences have also been proposed, although no clear environ-
mental predisposition has emerged from epidemiological studies
[Kallen et al., 2000; Martinez-Frias et al., 2001; Boyadjiev et al.,
2004; Keppler-Noreuil et al., 2007].
Here, we report on a genetic analysis of 13 individuals with
OEIS complex. For this analysis we considered that it was
important to analyze only OEIS cases and not isolated BE. To
identify pathogenic copy number variations (CNVs) that might
be responsible for the OEIS phenotype, we performed high
resolution SNP and oligonucleotide microarrays on our patient
cohort. We also sequenced 14 candidate genes that were predicted
to cause an OEIS complex phenotype in humans based on
caudal and/or urogenital defects in humans or in mouse models
and/or expression patterns. Although no pathogenic mutations
were identified in our patient sample, this is the most compre-
hensive genetic analysis of patients with OEIS complex to date.
Based on our data, we can conclude that OEIS complex is unlikely




Written informed consent was obtained from all study participants
in accordance with approved protocols from the Institutional
Review Board of the University of Michigan. Clinical features of
the 13 patients included in this study are shown in Table I. All
patients had at least two of the cardinal features of OEIS complex,
with the majority having all four cardinal features. One sample
(Patient 19) was from a fetus with the characteristic ultrasound
findings of OEIS complex. DNA was isolated from blood or buccal
samples using the Gentra Puregene DNA isolation kit (Qiagen-
USA, Valencia, CA) per manufacturer instructions. Buccal DNA
samples were obtained only from parents for confirmatory testing.
PCR and DNA Sequencing of Candidate Genes
PCR was performed in 20ml reaction volumes containing 1mM
forward and reverse primers and 1 Taq-Pro Complete (Denville
Scientific, Metuchen, NJ). PCR cycling was performed in an
Eppendorf Mastercycler (Eppendorf North America, Westbury,
NY) with conditions as follows: initial denature 95C for 15 min, 25
cycles 95C for 30 sec, 72C0.7C/cycle for 30 sec, 72C for 1 min,
21 cycles 95C for 30 sec, 55C for 30 sec, 72C for 1 min, followed
by a single 72C extension for 10 min. PCR primer sequences are
available by contacting the corresponding author. PCR results were
analyzed on 1% agarose gels electrophoresed in 1 Tris-acetate
buffer. PCR products were purified using Qiagen PCR purification
columns (Qiagen-USA) and sequenced by the University of Mich-
igan DNA sequencing core. Sequence analysis was performed by
aligning patient DNA sequences to the human genome consensus
sequence (hg18/build 36, released March 2006 as viewed at http://
www.genome.ucsc.edu) using the Sequencher computer program
(GeneCodes, Ann Arbor, MI). All DNA changes identified were
compared to known polymorphisms located in dbSNP (http://
www.ncbi.nlm.nih.gov/projects/SNP/). Changes identified as nov-
el were tested in parental DNA samples when available.
Mutation Analysis of the MT-RNR1 Gene
Mutation screening of the mitochondrial chromosome at position
1555 within the MT-RNR1 gene was performed by PCR and RFLP
analysis as previously described [Nye et al., 2000].
TaqMan Assays
TaqMan DNA copy number assays were performed on an ABI7500
Real-Time PCR System (Applied Biosystems, Foster City, CA).
Reactions were performed in 25ml volumes containing 1 FAM-
labeled locus specific TaqMan gene copy assay, 1 VIC-labeled
RNase P copy number reference assay, 1TaqMan gene expression
master mix, and 40 ng template DNA. Cycling conditions were
hold/denature 95C for 10 min, followed by 40 cycles of 95C for
15 sec, 60C for 60 sec. The manual CT threshold of the ABI7500 was
set to 0.2, and the autobaseline was on. Taqman assay Hs04956436_
cn representing the CHN2 gene and assay Hs00345272_cn repre-
senting the ANKYF1 gene were used for patients number 1 and
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number 9 respectively. A control assay (Hs05018555_cn) was also
performed to detect a deletion carried by patient 11 mapping to
chromosome 7p21.3. All reactions were performed at least two
times in triplicate. DNA copy number was calculated using Applied
Biosystem’s CopyCaller software version 1.0 comparing locus
specific copy number to the RNase P control.
SNP Chip Analysis
DNA for microarray analysis was purified over a QIAamp spin
column (Qiagen, QIAGEN Benelux B.V., KJ Venlo, the
Netherlands) followed by digestion with NspI. Specific adaptors
were ligated and fragments of 200–1,000 bp were amplified via
optimized PCR conditions. The amplified DNA was then frag-
mented, labeled, and hybridized to a GeneChip Mapping 250K SNP
Array (Affymetrix, Santa Clara, CA). The 250K SNP microarray was
run on the GeneChip Scannner 3000 7G with autoloader, GeneChip
Fluidics station 450, and GeneChip Hybridisaton oven 640
(Affymetrix).
The 250K SNP data were analyzed with GeneChip Genotyping
Analysis Software (GTYPE, Affymetrix), which uses an automated,
model-based genotype-calling algorithm that provides a confi-
dence score for each individual genotype. Copy number estimates
were determined automatically using the CNAG 2.0 software
package by a hidden markov model [Nannya et al., 2005]. Micro-
deletions and duplications detected by SNP microarray analysis
were first compared to an in-house reference dataset of patients
with disorders other than OEIS complex as well as to the Database of
Genomic Variants (http://projects.tag.ca/variation). Copy number
changes that occur as non-pathogenic variants in the human
genome were excluded from further analysis.
Oligo Array Analysis
In separate tubes, 1,010 ng of patient genomic DNA and of sex-
mismatched pooled reference genomic DNA were double-digested
with the restriction enzymes AluI and RsaI (Promega, Madison,
WA) and then fluorescently labeled with Cy3 and Cy5 respectively,
using the Genomic DNA Labeling Kit Plus (Agilent Technologies,
Santa Clara, CA). Labeled DNA samples were cleaned up of reagents
and unincorporated dyes by vacuum filtration using the Multi-
Screen HTS Filtration plates (Millipore, Billerica, MA) and re-
suspended in 22ml of 1 tris-EDTA. Purified fluorescently labeled
patient and reference DNAs were mixed together, and hybridized
to an Agilent 244K oligonucleotide array using standard reagents
and protocols supplied by the array manufacturer (Agilent
Technologies). Arrays were hybridized for 404 hr, and washed
using Agilent wash procedure B.
Arrays were scanned on a GenePix 4200A scanner (Molecular
Devices, Sunnyvale, CA), enclosed in a NoZone TL Workspace,
using GenePix Pro 6.1 software. Gains and losses were called
according to interpretation criteria established by the International
Standard Cytogenomic Array (ISCA) Consortium, as described in
Baldwin et al. [2008]. The resulting log2 derivatives of the patient/
control signal intensity ratios were plotted relative to the genomic
location of the corresponding probes. For detection of gains or
losses the thresholds for the log2 ratios were set at 0.32 for losses
and 0.26 for gains. A minimum of 4 contiguous oligonucleotide




Affymetrix 250K SNP arrays were run on seven patient samples
from our cohort. DNA gains and/or losses were detected in
four patient samples tested, and a total of 11 different changes
were identified (Table II). Ten of the changes were unique, while
one occurred in three of the seven samples tested. The recurrent
change is a duplication mapping to chromosome 17q21.31 covering
bases 41,521,621–41,647,903 (March 2006 human genome build
(hg18) as displayed on the UCSC Genome Browser). The DNA that
is duplicated in our patients flanks a known disease locus. Deletion
TABLE II. Copy Number Variation Identified by SNP Array
Patient Chromosome band Location Type Change
#1 7p15.1 29165987–29510059 Gain þ1
17q21.31–q21.32 41513416–42150418 Gain þ1
#2 5q21.1 101110353–101122504 Gain þ1
11p15.1 18907033–18918255 Gain þ1
17q21.31–q21.32 41521621–41647903 Gain þ1
22q11.1 15268818–15659603 Gain þ1
Xp22.31 7355904–7413831 Loss 1
#9 17p13.2 3945948–4270085 Gain þ1
18q12.1 27230880–27295732 Gain þ1
4p15.31 18595704–18733330 Loss 1
6q21 110348917–110400167 Loss 1
#11 7p21.3 8735273–8961255 Loss 1
17q21.31–q21.32 41474846–41707706 Gain þ1
Copy number changes were not identified in patients #4, #5, and #6.
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of the MAPT locus on chromosome 17q21.31 is a known cause of a
syndrome characterized by mental retardation and dysmorphic
features [Koolen et al., 2006]. However, the region we identified as
duplicated in our patient cohort is distal to this known genomic
disorder, is reported to be extremely polymorphic for copy number,
and is well represented in the database of genomic variants. Of the
ten remaining regions, six were present in the database of genome
variants and were not investigated further. Two regions identified
were not found in the database of genomic variants, but did not
contain any genes, and were not identified in more than one patient
sample.
In two patient samples we identified changes not completely
represented in the database of genomic variants, each containing
coding DNA sequences. Patient 1 carries a 344 kb pair duplication
of chromosome 7p15.1 spanning bases 29,165,987–29,510,059
(Fig. 1A,C). The duplication contains the beta chimerin gene
(CHN2; GenBank Accession: NM_004067). The proximal break-
point of this duplication maps within intron 9 of the CHN2 gene
and as such could result in functional monosomy of the gene if the
duplicated region is inverted or could result in a dominant negative
allele if the duplicated region is in tandem. In patient 9 we identified
a 324 kb pair duplication of chromosome 17p13.2 spanning bases
3,945,948–4,270,085 containing four genes (Fig. 1B,D). Three of
the genes are wholly duplicated resulting in trisomy; cytochrome b5
domain containing 2 (CB5D2; GenBank Accession: NM_144611),
ankyrin repeat and FYVE domain containing 1 (ANKFY1; GenBank
Accession NM_016376), and ubiquitin-conjugation enzyme E2G 1
(UBE2G1; GenBank Accession: NM_003342). A fourth gene, zinc
finger ZZ-type and EF hand domain containing protein 1 (ZZEF1;
GenBank Accession NM_015113) spans the distal breakpoint of the
duplication. Both of these novel regions were further studied using
Taqman assays in order to validate the data and test parental DNA
to determine segregation.
Oligo Array Analysis
244K Agilent oligo array assays were performed on seven patients
from our cohort; the sample from Patient 11 was assayed with
both the Affymetrix SNP and Agilent oligo arrays. Both genomic
aberrations carried by Patient 11 identified by SNP analysis
were confirmed by the oligo array. In addition, the oligo array
identified 11 additional copy number variations in the sample from
Patient 11 (see supporting information Table I which may be found
in the online version of this article). All of the additional variants
identified via oligo array in this sample were present in the database
FIG. 1. Genomic duplications identified by SNP array. SNP data indicating the duplications carried by (A) Patient 1 on chromosome 7p15.1 and
(B) Patient 9 on chromosome 17p13.2. The ideograms show the affected chromosome and banding patterns below the dosage of each SNP studied as
indicated by red dots. The spike in the SNPs shows the duplications as indicated by an increase in the horizontal blue line and marked with an asterisk.
The physical maps of the regions affected including the affected SNPs and genes are shown in (C) for Patient 1 and (D) for Patient 9 from the UCSC
Genome Browser (http://www.genome.ucsc.edu). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com]
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of genomic variants, and thus are not likely causative of the OEIS/
EC phenotype.
Numerous CNVs were identified in the additional six patient
samples (see supporting information Table I which may be found in
the online version of this article). Patient 14 carries 23 changes, the
highest number of identified changes within our cohort. In con-
trast, patient 11 carries 13 changes, the fewest we identified. We
identified three CNVs each recurring in five different patient
samples (see supporting information Table I which may be found
in the online version of this article). These are well known copy
number polymorphisms mapping to chromosomes 6p21.32 (HLA
locus), 17q21.31 (also identified in our SNP array studies), and
22q11.23. In total our oligo array analysis identified an average of
19.2 changes per sample within our cohort. All of the changes
identified via oligo array analysis were either present in the database
of genomic variants or were deemed unlikely to be causative of the
OEIS/EC phenotype based on the known or proposed function of
the gene(s) therein and were not investigated further.
TaqMan Assays
TaqMan assays were performed in order to validate the novel DNA
copy number changes identified by SNP chip analysis in Patients 1
and 9. The 344 kb pair duplication of chromosome 7p15.1 carried
by Patient 1 was tested using a TaqMan assay mapping within intron
1 of the CHN2 gene with a standard RNase P assay as a copy number
control. The probe location within intron one is roughly located in
the middle of the duplicated DNA segment. The CHN2 TaqMan
assay results confirmed the duplication identified in Patient 1 via
SNP chip analysis. However, the assay also indicated that both
parents are also heterozygous for this duplication and carry three
copies of this locus (Fig. 2A).
A TaqMan assay located in the 30 untranslated region of the
ANKFY1 gene was used to verify the duplication of chromosome
17p13.2 identified by SNP chip analysis in Patient 9. The ANKYF1
TaqMan assay we performed is located roughly in the middle
of the reported duplication. The assay when compared to the
RNase P control probe indicated that the patient carries three
copies of this locus (Fig. 2B). Our results also indicated that the
father is heterozygous for this duplication, and the mother is
actually homozygous for the duplication (has four copies). Thus,
it is unlikely that this duplication is causally related to the OEIS/EC
phenotype.
As an additional validation of our array CGH results, we also ran
assay Hs05018555_cn mapping to chromosome 7p21.3. This assay
detects a deletion carried by Patient 11 that was found by both the
SNP and oligo array. The deletion was confirmed in Patient 11 and
we found it was inherited from the patient’s father (data not
shown).
Candidate Gene Analysis
A candidate gene approach was undertaken to determine possible
single gene mutations causing the OIES/EC phenotype. We per-
formed a thorough search of the published literature to identify
genes that are known to play a role in caudal dysgenesis and/or
urogenital malformations in both human and mouse models. This
search revealed 14 candidate genes for analysis (Table III). Direct
DNA sequencing of all the exons and exon/intron boundaries of
these 14 candidate genes did not reveal any disease-causing
mutations.
We identified a total of 48 different DNA changes in our analysis.
Thirty eight of these changes were single nucleotide polymorphisms
(SNPs) that are present in the database of SNPs (dbSNP) and as
such were deemed not disease causing and were not tested for
parental segregation (Table IV). We also identified 10 DNA changes
that were novel and not present in dbSNP (Table V). Six of these
novel changes mapped to intronic DNA, did not uncover a cryptic
splice site, and were not investigated further. Within the IHH gene
we identified a single C–T transition within exon 3 in Patient 6,
which changes an arginine to a leucine. However, the mother of this
patient carries the same DNA change.
FIG. 2. Copy number analysis via TaqMan assay. (A) Assay Hs_04956436_cn mapping to the CHN2 gene indicates a duplication carried by Patient 1 as
well as both parents. (B) Assay Hs_0034272_cn mapping within the ANKFY1 gene on chromosome 17 indicates that Patient 9 and her father carry
three copies of this locus, while her mother carries four copies.
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Two changes were found in the 50 untranslated region of the
WNT3 gene. In each case, the only parent available for analysis did
not carry the change. Because only one parent was available we
screened a panel of 100 DNA samples from apparently healthy
individuals. The T–A transversion identified in Patient 14 was not
found in 100 control samples, while the C–A transversion identified
in patient 15 was identified in 1 of the 100 control DNA samples
screened and thus is likely a rare polymorphism.
In the FGF8 gene we identified an 18 bp duplication within exon
3 carried by Patient 9. Since the duplication does not shift the frame,
the additional bases result in the duplication of 6 amino acids in the
protein. Segregation analysis revealed that the mother of Patient 9
also carries the duplication in FGF8. One hundred control indi-
viduals of a similar ethnic background (Northern European
Caucasian) were tested for this duplication, and none of the
individuals carried the duplication. The six duplicated amino acids
are not located in a conserved domain of the FGF8 protein.
A mutation in the 12S ribosomal RNA gene located on the
mitochondrial chromosome (MT-RNR1; GenBank Accession
NC_012920 region 648–1,601) has previously been reported in
the proband from a family exhibiting maternally inherited pigment
anomalies and aminoglycoside-induced deafness [Nye et al., 2000].
In addition the proband also presented with myelocystocele-cloacal
exstrophy. The mitochondrial A1555G mutation was found in the
proband (exhibiting deafness and EC) as well as all deaf members of
the pedigree. We tested all patients in our cohort for the mitochon-
drial A1555G mutation. None of the patients in our OEIS/EC
cohort carried this mitochondrial mutation.





Band # exons Sequencing rationale Refs.
BMP4 NM_130851 14q22.2 4 Highly expressed in the tail bud, responsible for
differentiation in developing kidney in mouse
Brenner-Anantharam et al. [2007]
CYP26A1 NM_000783 10q23.33 6 Knock-out mouse mutants die mid-gestation and
show tail truncation, fused kidneys, blind ending
hindgut, and abnormal urogenital sinus
Sakai et al. [2001]
DHH NM_021044 12q13.12 3 DHH mutations in humans cause partial gonadal
dysgenesis. Dhh null mice are infertile and have
peripheral nerve abnormalities
Bitgood et al. [1996],
Umehara et al. [2000]
EFNB2 NM_004093 13q33.3 5 Efnb2 mutant mice display hypospadias, persitant
cloaca, and anorectal malformations
Dravis et al. [2004]
FGF8 NM_033164 10q24.32 6 Fgf8 null mice fail to gastrulate and die E10.5.
Highly expressed in the tail bud
Crossley and Martin [1995],
Sun et al. [1999]
IHH NM_002181 2q35 3 Ihh mutant mice have malrotation, hypoplastic villi,
and Hirschsprung-like phenotype in colon. Ihh/Shh
double null mice have open gut
Ramalho-Santos et al. [2000],
Zhang et al. [2001]
p63 NM_003722 3q28 14 p63 null mice have bladder exstrophy. p63 mutations
in humans cause ectrodactyly, ectodermal dysplasia,
and facial clefts and other malformation syndromes
Brunner et al. [2002],
Cheng et al. [2006]
PCSK5 NM_006200 9q21.13 21 Mutation in mouse Pcsk5 causes a VACTERL/caudal
regression phenotype
Szumska et al. [2008]
SHH NM_000193 7q36.3 3 Mutations of Shh in mouse cause duodenal stenosis,
abnormal gut innervation, and imperforate anus.
Important for formation of cloaca and hindgut
Haraguchi et al. [2007];
Ramalho-Santos et al. [2000]
T NM_003181 6q27 8 Transcription factor required for proper mesoderm
formation. Classic mouse mutation affecting tail
length, sacral vertebrae, and the notochord
Herrmann et al. [1990]
TBX6 NM_004608 16p11.2 8 Tbx6 null mouse embryos lack caudal somites and
form ectopic neural tubes
Chapman and Papaioannou
[1998]
WNT3 NM_030753 17q21.32 5 Wnt3 null mice fail to form primitive streak and
mesodermal tissue. Homozygous mutation of WNT3
shown to cause tetra-amelia and urogenital
defects in a single family
Liu et al. [1999],
Niemann et al. [2004]
WNT3A NM_033131 1q42.13 4 Wnt3a null mice have complete absence of tailbud,
lack caudal somites, and have disrupted notochord;
vestigial tail mouse mutant a hypomorphic allele
of Wnt3a
Greco et al. [1996],
Takada et al. [1994]
WNT9B NM_003396 17q21.32 5 Regulates epithelial transition during urogenital
organogenesis
Carroll et al. [2005]
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DISCUSSION
OEIS complex is a rare developmental field defect of unknown
etiology. A significant genetic component is suspected based on the
presence of familial cases and a higher concordance rate in mono-
zygotic twins, yet no causative genes have been identified [Reutter
et al., 2007b; Ludwig et al., 2009a]. The accumulating evidence for a
strong genetic component as an underlying etiology for OEIS
complex prompted us to perform a comprehensive genetic analysis
of 13 individuals with OEIS complex. We sequenced 14 candidate
genes and performed high resolution genomic arrays using either a
250K SNP array or a 244K oligonucleotide array. No causative
mutations or genomic aberrations were identified in our patient
cohort.
OEIS complex has been reported in association with Trisomy 21,
Trisomy 18, Triple X syndrome, Turner mosaicism, and 1p36
deletion [Ludwig et al., 2009a; El-Hattab et al., 2010]. However,
given the relatively high prevalence of these chromosomal disorders
in the general population, it is unlikely that OEIS complex is
causally associated with these chromosomal aberrations. Two
patients with cloacal exstrophy and chromosomal deletions have
been reported: one patient carrying an unbalanced translocation
between chromosome 9 and the Y chromosome, resulting in
monosomy for chromosome 9q34.1-qter, and one patient with
del(3)(q12.2q13.2) [Thauvin-Robinet et al., 2004; Kosaki et al.,
2005]. One additional patient with OEIS complex and hypomela-
nosis of Ito has been reported [Leonard and Tomkins, 2002]. This
patient was mosaic for a cell line with t(1;6) (p32;q13) in fibroblasts.
TABLE IV. Known SNPs Identified During Candidate Gene Sequencing





BMP4 rs2761880 A>G N/A Intron 3 0 13
rs17563 T>C V>A Exon 2 5 6
CYP26A1 rs74151825 A>G N/A Intron 2 1 0
EFNB2 rs7995379 C>G G>G Exon 5 0 13
IHH rs394452 G>A T>T Exon 3 5 7
rs3731878 G>A T>T Exon 3 1 0
rs3731881 T>C P>P Exon 3 7 6
P63 rs17514215 T>G N/A Intron 5 1 1
rs33979049 C>T L>L Exon 6 1 0
rs6790167 A>G N/A Intron 9 6 3
PCSK5 rs7020560 G>A L>L Exon 1 1 0
rs7040769 T>C C>C Exon 1 3 0
rs4745472 G>A N/A Intron 1 0 1
rs2297344 C>A N/A Intron 7 4 2
rs1416547 T>G N/A Intron 8 5 1
rs2377429 T>C N/A Intron 8 6 0
rs2297343 C>T N/A Intron 9 1 1
rs41310061 G>A T>T Exon 9 1 0
rs3824474 A>G N/A Intron 11 1 0
rs2297342 G>A S>S Exon 12 2 2
rs10124541 C>T P>P Exon 14 1 0
rs2270570 A>G N/A Intron 16 5 1
rs1537183 G>A N/A Intron 16 0 13
rs7046850 T>C N/A Intron 17 1 0
rs10869726 G>A N/A Intron 20 2 0
SHH rs1233554 T>G N/A Intron 3 6 7
rs1233555 G>A N/A Intron 2 9 4
T rs1056048 C>T S>S Exon 3 2 2
rs2305089 G>A G>D Exon 4 4 5
rs9459599 G>A N/A Intron 5 2 2
rs3127328 G>A G>G Exon 8 1 1
rs35819705 G>A A>A Exon 8 0 2
TBX6 rs3809624 A>G N/A 30 UTR 2 0
WNT9B rs4968281 T>C T>M Exon 2 3 8
rs11654422 G>A N/A Intron 2 4 3
rs11654424 G>A N/A Intron 2 4 3
rs34072914 G>T R>R Exon 3 1 0
rs754474 G>C V>V Exon 4 2 0
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A causal relationship between this translocation and OEIS complex
is unclear. Chromosomal aberrations have also been reported in
patients with BE and epispadias [Ludwig et al., 2009a]. However, no
recurrent chromosomal aberrations have been identified either for
OEIS complex or BE.
Several other studies examining candidate genes in patients with
OEIS complex or BEEC have been performed. In general, these
studies have examined one candidate gene in a small number of
individuals. The homeobox gene HLXB9, which is mutated in
Currarino syndrome (OMIM #176450) [Ross et al., 1998], was
sequenced in bladder DNA of five patients with OEIS/EC and
leukocyte DNA from five patients with bladder exstrophy, and no
mutations were identified [Boyadjiev et al., 2004]. Because of their
respective genomic localizations near a reported translocation in a
patient with OEIS complex, the NR5A1 (Steroidogenic factor-1)
gene on 9q33.3 was analyzed in 1 patient with OEIS complex
[Thauvin-Robinet et al., 2004], and the SET gene (Suppressor of
variegation, Enhancer of Zeste and Trithorax) on 9q34.11 was
analyzed in 33 patients with BEEC [Reutter et al., 2006]. No
causative mutations were identified in either gene. Because of its
localization at 9q13, which has been implicated in two independent
translocations in BE, the CNTNAP3 gene was analyzed in several
patients with BE, but no association was found [Boyadjiev et al.,
2005]. The FGF10 gene was analyzed in 10 patients with OEIS
because of its known role in urethral plate fusion based on mouse
knockout models [Kruger et al., 2008]. Similarly, the TRP63 gene
was analyzed based on the bladder exstrophy phenotype of the
DNp63 knockout mouse [Cheng et al., 2006; Ching et al., 2007].
Again, no causative mutations were identified in either gene. In one
patient with OEIS complex and aminoglycoside-induced sensori-
neural hearing loss, a mutation in the mitochondrial 12S RNA gene
was identified [Nye et al., 2000]. However, the mutation in this
family segregated with the hearing loss phenotype. Although other
family members carrying the 12S RNA mutation had minor uro-
genital anomalies, a causative relationship between the 12S RNA
gene and OEIS complex could not be established. Furthermore, this
mutation was not identified in any of the patients in our cohort.
The candidate genes in this study were chosen based on several
different criteria. (1) Mouse knockout models with caudal or
urogenital phenotypes, (2) a known role for the candidate gene in
caudal and/or urogenital development in humans, or (3) embry-
onic expression patterns which suggest a potential role in caudal
and/or urogenital development. We did not identify any point
mutations that were unequivocally causative of the OEIS/EC
phenotype. We did identify several known SNPs in our study, as
well as a number of novel DNA changes. With the exception of
variants in the 50 untranslated region of the WNT3 gene in two
patients, all of the other novel DNA changes were also carried by at
least one unaffected parent. The novel variants identified in the
WNT3 gene were not present in an unaffected parent, although only
one parent was available for analysis. Although mutation of WNT3
has been associated with urogenital malformations and tetra-
amelia in one consanguineous family [Niemann et al., 2004], this
recessive nonsense mutation likely led to loss of function of the
gene, and the heterozygous carrier parents were normal. Intrigu-
ingly, the FGF8 duplication variant was not found in a control
population of 100 individuals (200 chromosomes). Although sin-
gularly none of these changes are likely sufficient to cause OEIS/EC,
we cannot rule out that they are associated with the disease
phenotype. However, the rarity of this disorder limits our ability
to obtain a sufficiently large patient cohort to perform the necessary
statistical analysis to adequately test this hypothesis.
Only limited whole genome studies in patients with OEIS
complex have been reported. One patient carrying a deletion of
3q12.2q13.2 was identified using bacterial artificial chromosome
aCGH [Kosaki et al., 2005]. A copy number variant (CNV) was
identified in a consanguineous family with three affected members
with BE; however, this was a well known CNV on 1p21.1 encom-
passing the pancreatic and salivary amylase genes; thus it is unlikely
related to the BE phenotype [Reutter et al., 2007a]. More recently, a
genome-wide association study was performed in two BE families:
one nonconsanguineous family with two affected family members
and one consanguineous family with two affected family members
[Ludwig et al., 2009b]. Although several genomic loci were identi-
fied with LOD scores of >1.5, a causative role for any of these
regions remains to be established. Furthermore, these studies are
based on an autosomal recessive mode of inheritance for BEEC,
which has not definitively been established in the literature.
We utilized two different aCGH platforms in our study: a 250K
SNP array and a 244K oligonucleotide array. We observed greater
TABLE V. Novel SNPs Identified During Candidate Gene Sequencing
Gene Patient DNA change Amino acid change Location Nomenclaturea
CYP26A1 13 G>C N/A Intron 2 IVS2þ86G>C
15 G>C N/A Intron 2 IVS299G>C
FGF8 9 18 bp duplication 6 duplicated Exon 3 c.104_121dupAGCTCGCTTCCCTGTTCC
IHH 15 C>T N/A Intron 1 IVS1þ49C>T
05 G>A R>L Exon 3 c.1169G>A
PCSK5 05 T>A N/A Intron 16 IVS16þ58T>A
SHH 14 C>T N/A Intron 3 IVS370C>T
WNT3 14 T>A N/A 50 UTR c.73T>A
15 C>A N/A 50 UTR c.86C>A
WNT9B 9 T>C N/A Intron 2 IVS2þ86T>C
aNomenclature based on following accession numbers: CYP26A1:NM_000783, FGF8:NM_033163, IHH:NM_002181, PCKS5:NM_006200, WNT3:NM_030753, WNT9B:NM_003396.
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sensitivity with the oligonucleotide array. In the one sample that
was analyzed on both platforms, the two CNVs that were identified
by the SNP array were also identified by the oligo array, as well as 11
additional CNVs. However, higher density SNP arrays are now
available that may improve the sensitivity of the SNP arrays. While
we identified numerous CNVs in our patient cohort, the majority
were known CNVs that are well represented in the database of
genome variants. In addition, the only recurrent CNVs in our
patient cohort are well known to be widely polymorphic. The CNVs
that we identified that were not represented in the database of
genome variants were both validated by TaqMan assay and were
found to be present in at least one unaffected parent. Therefore,
individually, none of the CNVs that we identified are likely to be
causally associated with the OEIS complex phenotype. However, we
cannot rule out the possibility that one or more of these CNVs may
be a genetic risk factor for development of the OEIS complex
phenotype in combination with other environmental or genetic
risk factors [Klopocki et al., 2007]. Further, it is also possible that
one of the CNVs could have unmasked a recessive mutation at one
of these loci. Sequencing of the candidate genes contained within
these CNVs in the other affected individuals could help to clarify
this possibility.
Based on our current knowledge of OEIS complex, the majority
of individuals represent sporadic cases, and the recurrence risk
for future pregnancies is thought to be low. Although other
modes of inheritance cannot be completely excluded, this is
most consistent with a de novo mutation in a gene that affects
development of caudal and urogenital structures. Because so few
affected individuals reproduce, it is difficult to know whether
these affected individuals would pass along the complete OEIS
complex phenotype to their offspring. For the few familial cases,
the inheritance pattern has been most consistent with autosomal
dominant inheritance with reduced penetrance and/or variable
expressivity, influenced either by other genetic or epigenetic
factors [Keppler-Noreuil, 2001; Boyadjiev et al., 2004]. Recently,
it has been proposed that the Disorganization gene (Ds) in mice
may represent a model for OEIS complex including limb malfor-
mations in humans [Robin et al., 2007]. Ds mice have variable
phenotypes that can resemble OEIS complex, and the penetrance
is known to be low. However, since the Ds gene has not yet been
identified, it is impossible to prove or disprove this interesting
theory.
At this time, the pathogenesis of OEIS complex remains elusive.
The lack of a single genetic etiology precludes the creation of an
animal model, and the lack of an animal model that completely
recapitulates the phenotype limits the ability to study developmen-
tal pathways and isolate candidate genes. It is most likely that OEIS
complex is a developmental field defect of the cells comprising the
caudal eminence, and perturbation of this region at specific time
points during development, either by genetic or environmental
factors, leads to the OEIS complex phenotype.
While no causative genetic explanation was found in this study, it
is still likely that there are as of yet unidentified genes that strongly
contribute to the OEIS complex phenotype, and additional research
is needed. Although a large number of candidate genes were
analyzed in this study, we cannot rule out that a mutation in one
of these genes could cause an OEIS complex phenotype in rare
patients, or that some of the rare variants that were found are
associated with the disease phenotype and have reduced penetrance
in unaffected parents. While we did not identify any unique
recurrent CNV that might contain a candidate gene for OEIS
complex, we also cannot exclude the possibility that rare CNVs
might cause OEIS complex. However, it is unlikely that OEIS
complex is caused by a recurrent genomic CNV.
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